IMRX earnings analysis
What we found in IMRX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Immuneering reported a Q1 2026 net loss of $13.5 million, improving from a loss of $15.0 million in Q1 2025. Despite not disclosing revenue figures, the company maintained a cash position of $198.6 million, securing operational funding into 2029. Management discussed ongoing clinical trials for their lead product atebimetinib, amidst a backdrop of reduced R&D expenses and increased interest income.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Improved EPS Compared to Last Year
- Q1 2026 EPS improved to -$0.21 from -$0.42 in Q1 2025.
- Reduced R&D Expenses
- R&D expenses decreased 7.2% to $10.645 million from $11.472 million year-over-year.
- Significant Cash Reserves
- As of March 31, 2026, the company had $198.6 million in cash, ensuring operations through 2029.
- Increased Interest Income
- Interest income rose to $1.36 million from $439,000 a year prior, reflecting improved cash balances.
- Upcoming Clinical Trials
- Atebimetinib's Phase 3 clinical trial, MAPKeeper 301, is set to start mid-2026.
- Positive Clinical Data
- Positive interim data from the Phase 2a trial was announced in January 2026, supporting atebimetinib's potential.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ongoing Operational Losses
- The company reported a net loss of approximately $13.5 million for Q1 2026, contributing to an accumulated deficit of $293.8 million.
- Dependence on Future Funding
- To finance operations beyond 2029, additional capital will be needed, which could constrain operational capability.
- Regulatory Approval Uncertainties
- FDA approval is pending for atebimetinib; any failures could substantially affect financial prospects.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.21
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads better than the one before it.
What came before.
- 10-K · March 6, 2026
- Immuneering is a late-stage clinical oncology company commercializing a novel 'Deep Cyclic Inhibitors' approach, with lead candidate atebimetinib (320 mg QD) advancing toward a global Phase 3 (MAPKeeper 301). The…
- 10-Q · August 13, 2025
- Immuneering reported a GAAP net loss of $14,433,881 for the quarter ended June 30, 2025 (net loss per share $(0.40)), with cash and cash equivalents of $26,355,498 as of June 30, 2025. Management raised equity via an…
- 10-K · March 1, 2024
- Immuneering is a clinical-stage oncology company developing 'deep cyclic inhibition' small-molecule programs (lead candidates IMM-1-104 and IMM-6-415) and reports early clinical/translational progress (IND clearances,…
- 10-Q · November 9, 2023
- Immuneering reported no product revenue for the quarter (Revenue $—) and a net loss of $12,595,211 (EPS $(0.43)) for the three months ended September 30, 2023, a modest EPS improvement versus the prior-year quarter EPS…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing IMRX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever